The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole

2021 ◽  
pp. 1-45
Author(s):  
Tetsuro Kikuchi ◽  
Kenji Maeda ◽  
Sakiko Yamada ◽  
Mikio Suzuki ◽  
Tsuyoshi Hirose ◽  
...  
2017 ◽  
Vol 235 (1) ◽  
pp. 99-108 ◽  
Author(s):  
Emilia Tarland ◽  
Robert T. Franke ◽  
Heidrun Fink ◽  
Heinz H. Pertz ◽  
Jan Brosda

2006 ◽  
Vol 552 (1-3) ◽  
pp. 36-45 ◽  
Author(s):  
Julia N. Heinrich ◽  
Julie Brennan ◽  
Margaret H. Lai ◽  
Kelly Sullivan ◽  
Geoff Hornby ◽  
...  

2009 ◽  
Vol 117 (1) ◽  
pp. 55-67 ◽  
Author(s):  
Michael John Jackson ◽  
Terrance H. Andree ◽  
Matthew Hansard ◽  
Diane C. Hoffman ◽  
Mark R. Hurtt ◽  
...  

2004 ◽  
Vol 19 (3) ◽  
pp. 190
Author(s):  
Tetsuro Kikuchi ◽  
Stark Arlene ◽  
Frank Yocca ◽  
Yoshihiro Tadori ◽  
Tsuyoshi Hirose ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Lakshmi Priya ◽  
Bini Moorthy

Aripiprazole is an antipsychotic with partial agonist activity at the dopamine D2 receptor which may lead to compulsive behaviors including hypersexuality. The case presented is of a 24-year-old male with schizophrenia who developed hypersexuality symptoms after initiation of aripiprazole. Cessation of the aripiprazole led to a reduction in hypersexual behaviors. Clinicians should be aware of compulsive behaviors including hypersexuality with aripiprazole use and consider discontinuation of aripiprazole treatment in patients suffering from hypersexuality.


PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e46488 ◽  
Author(s):  
Hiroshi Ito ◽  
Harumasa Takano ◽  
Ryosuke Arakawa ◽  
Hidehiko Takahashi ◽  
Fumitoshi Kodaka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document